Immutep (IMMP) vs Lite Strategy (LITS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immutep (IMMP) has outperformed Lite Strategy (LITS) over the past year, gaining 80.8% versus a loss of 52.8%. Over five years, IMMP leads with a -8.5% price change compared with -98.5% for LITS. Lite Strategy is the larger company by market cap ($24.0 million vs $22.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | LITS |
|---|---|---|
| Share price | $3.11 | $0.8026 |
| Market cap | $22.92M | $23.99M |
| 1-day change | -9.06% | -4.03% |
| YTD return | +8.74% | -39.20% |
| 1-year return | +80.81% | -52.79% |
| 5-year return | -8.53% | -98.46% |
| EPS (TTM) | $-7.30 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-71.15M |
| 52-week high | $70.60 | $1.99 |
| 52-week low | $2.66 | $0.69 |
| Distance from 52-week high | -95.59% | -59.67% |
| Analyst consensus | none | — |
| Avg. price target upside | +864.63% | — |
| Average volume | 26.07K | 524.33K |
| Shares outstanding | 7.37M | 29.88M |
| Employees | — | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed LITS by 133.6 percentage points over the past year.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
IMMP vs LITS FAQ
Which is bigger, Immutep or Lite Strategy?
Lite Strategy (LITS) is larger, with a market capitalization of $23.99M compared with $22.92M for Immutep (IMMP).
Which stock has performed better over the past year, IMMP or LITS?
IMMP returned +80.81% over the past 12 months, compared with -52.79% for LITS (price return, excluding dividends). Past performance does not predict future results.
Are Immutep and Lite Strategy in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.